Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028

Fate Therapeutics

13/05/2026 13:40

Overview

Biopharmaceutical firm's Q1 collaboration revenue declined yr/yr

Q1 operating expenses fell 20% from prior year, extending cash runway into 2028

Company advanced clinical pipeline, including new regulatory milestones and upcoming Phase 2 trial

Outlook

Company expects to initiate Phase 2 RECLAIM-LN trial of FT819 in 2nd half of 2026

Fate Therapeutics plans to submit IND and start Phase 1 FT839 autoimmune study in 2nd half 2026

Company says operating runway extends into 2028

Result Drivers

OPERATING EXPENSE REDUCTION - Co said a 20% yr/yr decrease in operating expenses extended its cash runway into 2028

COLLABORATION REVENUE - Q1 revenue was derived from preclinical development activities under collaboration with Ono Pharmaceutical

Company press release: ID:nGNX8K3mMq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$1.3 mln
Q1 Net Income
-$31.21 mln
Q1 Basic EPS
-$0.26
Q1 Income from Operations
-$33 mln
Q1 Operating Expenses
$34.3 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Fate Therapeutics Inc is $6.00, about 166.7% above its May 12 closing price of $2.25

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)